Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Lymphoid 1

Conditions

Uterine Cervical Neoplasms 2Neuroendocrine Tumors 2Glioblastoma 2Vaginal Neoplasms 1Lymphoma, Follicular 1Endometrial Serous Adenocarcinoma 1Astrocytoma 1

Interventions

Temozolomide 41Magnetic Resonance Spectroscopy 21Radiotherapy 19Specimen Handling 15Radiation 12Bevacizumab 11Lomustine 9pembrolizumab 6fludarabine 5Surgical Procedures, Operative 5atezolizumab 4Nivolumab 4Ipilimumab 4Cyclophosphamide 4Carboplatin 4Biopsy 4cemiplimab 3azeliragon 3Immunoglobulin G 3Disulfides 3Aminolevulinic Acid 3veliparib 2trametinib 2rocakinogene sifuplasmid 2ribociclib 2poly ICLC 2pamiparib 2olaparib 2niraparib 2lutetium Lu 177 dotatate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 90 days × Clear all
NCT06860594 2026-06-05

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT06410248 2026-05-01

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Northwestern University

Phase 1 Recruiting
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡